FindTrial
Sign In

Het vaststellen van botmetastases in hormoon naïeve prostaatkanker in PET/CT met behulp van [18F]FDHT

[18F] -labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON27460
Enrollment
Unknown
Registered
2013-07-19
Start date
2013-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hormone naive prostate cancer metastasized to bone, hormoon naïve bot-gemetastaseerde prostaatkanker

Interventions

[18F]FDHT in PET/CT

Sponsors

UMCG
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • metastasized prostate cancer, ≥2 lesions in bone, confirmed by o visible lesions on bone scan, CT and/or MRI consistent with disease o age ≥ 50 years • no other known malignancies • written informed consent • no previous androgen deprivation therapy

Exclusion criteria

Exclusion criteria: • active cancer besides prostate cancer • age < 50 years • no written informed consent • previous androgen deprivation therapy • imminent pathological fractures or spinal cord lesions as a result of metastases that require immediate start of androgen deprivation therapy

Design outcomes

Primary

MeasureTime frame
Patients with metastasized prostate cancer will undergo a [18F]FDHT PET/CT before start of ADT. A second scan will be performed three months after start of ADT. Primary outcome is the amount of decreased uptake of 18F-FDHT per lesions before and after three months of ADT.—

Contacts

Public ContactR.J. Dost
rj.dost@umcg.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)